# Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor/Glucophage XR

> **NCT02185066** · PHASE1 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 42 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Atorvastatin 20mg and Metformin XR 500mg (Reference)
- **DRUG:** CJ-30056 20/500mg (Test)

## Key facts

- **NCT ID:** NCT02185066
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-09
- **Final completion:** 2014-11
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2016-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02185066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02185066, "Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor/Glucophage XR". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02185066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*